Key result
PARP-1 gene deletion significantly improved cardiac dysfunction and reduced inflammatory response and apoptosis in a mouse model of diabetic cardiomyopathy.
Why the study?
Diabetic cardiomyopathy development is closely linked to increased PARP-1 activity, and the mechanism by which liraglutide protects against myocardial injury in type 2 diabetes required investigation.
Does PARP-1 inhibition or liraglutide improve cardiac function and reduce inflammation and apoptosis in diabetic cardiomyopathy models?
Does PARP-1 inhibition or liraglutide improve cardiac function and reduce inflammation and apoptosis in diabetic cardiomyopathy models?
PARP-1 inhibition protects against diabetic cardiomyopathy by reducing inflammation and apoptosis, partly through the IGF-1R/Akt pathway.
Answers are grounded in this paper and cite their sources.
Liraglutide may reduce myocardial injury in diabetic rats via PARP-1; leaves open translation to human DCM.
BACKGROUND: In recent years, studies have found that the occurrence and development of diabetic cardiomyopathy (DCM) is closely related to an increase in polyadenosine diphosphate-ribose polymerase-1 (PARP-1) activity. PARP-1 activation could be involved in the pathophysiological process of DCM by promoting oxidative stress, the inflammatory response, apoptosis and myocardial fibrosis. AIM: To investigate the mechanism of liraglutide in improving myocardial injury in type 2 diabetic rats, further clarified the protective effect of liraglutide on the heart, and provided a new option for the treatment of DCM. METHODS: = 30), which were fed an ordinary diet and a high-sugar and high-fat diet, respectively. After successful modeling, the rats in the model group were fed a high-glucose and high-fat diet for 4 wk and randomly divided into a model group and an intervention group (further divided into a high-dose group and a low-dose group). The rats were fed a high-glucose and high-fat diet for 8 wk and then started drug intervention. Blood samples were collected from the abdominal aorta to detect fasting blood glucose and lipid profiles. Intact heart tissue was dissected, and its weight was used to calculate the heart weight index. Haematoxylin and eosin staining was used to observe the pathological changes in the myocardium and the expression of PARP-1 in the heart by immunohistochemistry. CONCLUSION: Liraglutide may improve myocardial injury in type 2 diabetic rats by inhibiting the expression of myocardial PARP-1 in a dose-dependent manner.
No takes yet. Share an insight, caveat, or question.
Xue et al. (2023) studied Diabetic cardiomyopathy (n=30). PARP-1 deletion vs. Wild-type diabetic mice was evaluated on Cardiac function, inflammation, and apoptosis (p=<0.05). PARP-1 gene deletion significantly improved cardiac dysfunction and reduced inflammatory response and apoptosis in a mouse model of diabetic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: